STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion

Loading TBN…

Briefings

Pathos AI, an artificial intelligence-driven drug development firm, raised $237 million in a Series E round led by Bristol Myers Squibb, increasing its valuation to approximately $3 billion. The company is expanding its focus from oncology to neurological conditions, utilizing datasets from Tempus AI and a new partnership with BMS to prioritize Alzheimer's treatments. Pathos claims its proprietary Foundry model uses thousands of agents to calculate success probabilities for clinical assets, analyzing data including genomics and biological specimens to guide trial design and population selection.

Key points

Pathos raised $237 million in a Series E round led by Bristol Myers Squibb, bringing its valuation to approximately $3 billion.

Pathos is expanding its focus from oncology to neurological conditions, utilizing datasets from Tempus AI and a new partnership with BMS to prioritize Alzheimer's treatments.

Context

Pathos is an artificial intelligence-driven drug development company that claims its proprietary Foundry model uses thousands of agents to calculate success probabilities for clinical assets. The company is expanding its focus from oncology to neurological conditions, utilizing datasets from Tempus AI and a new partnership with BMS to prioritize Alzheimer's treatments.

Limitations

Evidence is limited to the announcement of the $237 million Series E round and the expansion to neurological conditions. Specifics on the new partnership's scope, the exact number of agents in Foundry, or the timeline for Alzheimer's trials are not detailed in the provided text.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 13:09:14 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicbx7qf4pwtxqubextm7down66s7t2xvw7ft52cnj7mpp42pa4zhy